Visual Abstract

Background: In insulin-treated patients (pts) with T2DM, untreated severe hypoglycemia (SH) can be life-threatening. We used a healthcare claims database (db) to identify less established SH risk factors in this group.

Methods: Adults with T2DM and ≥1 insulin claim (2012-2018) were identified in IQVIA’s PharMetrics® Plus db. Cases with SH were matched to controls using incidence density sampling and exact matched on well‑known factors (age, sulfonylurea pharmacy claim, prior SH, renal disease). A conditional logistic regression model tested associations between potential risk factors and SH occurrence.

Results: In 3153 cases/3153 matched controls, mean ± SD age was 56.2 ± 10.9 years. Identified risk factors included pregnancy (odds ratio for exposure ≤1 mo before SH = 3.2, 95% CI 1.7-6.0) and pharmacy claims: short-acting insulin (2.2, 1.6-3.1), rapid-acting insulin (1.5, 1.3-1.7), anxiolytics (1.5, 1.2-1.9), antipsychotics (1.6, 1.1-2.2), corticosteroids (1.4, 1.1-1.7), opioids (1.4, 1.2-1.6), β-adrenergic agonists (1.4, 1.1-1.9). Higher comorbidity score, alcohol abuse and certain comorbidities also raised SH risk (Fig 1).

Conclusion: Acknowledging limitations of claims db analyses, our study identified certain comorbidities and medications (primarily within 1 mo of SH) as additional risk factors for SH. Such data may help facilitate interventions for pts with T2DM at increased SH risk.

Disclosure

J. Settles: Employee; Self; Eli Lilly and Company. C. J. Child: Employee; Self; Eli Lilly and Company, Stock/Shareholder; Self; Eli Lilly and Company. M. Gorritz: Consultant; Self; Amgen Inc., Eli Lilly and Company, Novartis Pharmaceuticals Corporation, Otsuka America Pharmaceutical, Inc., Takeda Pharmaceutical Co. J. K. Multani: Other Relationship; Self; Eli Lilly and Company. C. Mcguiness: Research Support; Self; AbbVie Inc., Allergan plc, Amgen Inc., Astellas Pharma Inc., Eli Lilly and Company, GlaxoSmithKline plc., Novartis Pharmaceuticals Corporation, Regeneron Pharmaceuticals Inc., Sanofi, Takeda Pharmaceutical Co. R. Wade: Research Support; Self; Eli Lilly and Company. H. Kan: Employee; Self; Eli Lilly and Company, Stock/Shareholder; Self; Bristol-Myers Squibb Company, GlaxoSmithKline plc.

Funding

Eli Lilly and Company

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.